Clinical and dermoscopic features of orf transmitted from camels
Abstract
1 Azevedo A, Bettencourt A, Selores M, et al. Biosimilar agents for psoriasis treatment: the perspective of portuguese patients. Acta M ed Port 2018; 31: 496–500. 2 Puig L, L opez-Ferrer A. Biosimilars for the treatment of psoriasis. Exp Opin Biol Ther 2019; 19: 993–1000. 3 Barker J, Girolomoni G, Egeberg A, et al. Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. J Dermatolog Treat 2019; 1–7. https://doi.org/10.1080/09546634. 2019.1610553. 4 Reynolds KA, Pithadia DJ, Lee EB, et al. Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review. Exp Opin Drug Saf 2020; 19: 459–466. 5 Reynolds KA, Pithadia DJ, Lee EB, et al. Safety and effectiveness of anti-tumor necrosis factor-alpha biosimilar agents in the treatment of psoriasis. Am J Clin Dermatol 2020; 21: 483–491.
Read the paper
Related studies
- In silico strategies for modeling RNA aptamers and predicting binding sites of their molecular targets
- Folic acid-hydrophilic polymer coated mesoporous silica nanoparticles target doxorubicin delivery
- Anti-phytopathogenic and plant growth promoting potential of endophytic fungi isolated from Dysoxylum gotadhora
- Mercury toxicity causes iron and sulfur deficiencies along with oxidative injuries in alfalfa (Medicago sativa)
- Suppression of lncRNA GAS6-AS2 alleviates sepsis-related acute kidney injury through regulating the miR-136-5p/OXSR1 axis in vitro and in vivo
- Assessing the Protective Effect of Moringa oleifera Extract against Bone Metastasis: An In Vitro Simulated Digestion Approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.